Efavirenz: Difference between revisions

Line 12:

==Pharmacology==

Pharmacologically, efavirenz is primarily classified as a non-nucleotide reverse transcriptase inhibitor, or NNRTI. Reverse transcriptase is an enzyme found in several viral species that is a type of DNA polymerase and nuclease that allows viruses like hepatitis and human immunodeficiency virus to transcribe viral RNA into DNA.

Pharmacologically, efavirenz is primarily classified as a non-nucleotide reverse transcriptase inhibitor, or NNRTI. Reverse transcriptase is an enzyme found in several viral species that is a type of DNA polymerase and nuclease that allows viruses like hepatitis and human immunodeficiency virus to transcribe viral RNA into DNA. Efavirenz is considered a non-nucleotide reverse transcriptase inhibitor because it does not have a structure based off of a nucleotide like

Unlike most non-nucleotide reverse transcriptase inhibitors, efavirenz is also a 5-HT<sub>2A</sub> partial agonist, similar to [[LSD]]. Additionally, efavirenz is a [[serotonin]] and [[dopamine]] [[reuptake inhibitor]] and a vesicular monoamine transporter 2 inhibitor. Efavirenz also acts as a [[GABA]]<sub>A</sub> positive allosteric modulator, similar to [[benzodiazepines]] and [[barbiturates]].<ref> Neuropsychopharmacology | http://www.nature.com/npp/journal/v38/n12/full/npp2013135a.html</ref> Efavirenz has a bioavailability of about 40-45% when it is taken on an empty stomach.

@@ Line 12: / Line 12: @@
 ==Pharmacology==
-Pharmacologically, efavirenz is primarily classified as a non-nucleotide reverse transcriptase inhibitor, or NNRTI. Reverse transcriptase is an enzyme found in several viral species that is a type of DNA polymerase and nuclease that allows viruses like hepatitis and human immunodeficiency virus to transcribe viral RNA into DNA.
+Pharmacologically, efavirenz is primarily classified as a non-nucleotide reverse transcriptase inhibitor, or NNRTI. Reverse transcriptase is an enzyme found in several viral species that is a type of DNA polymerase and nuclease that allows viruses like hepatitis and human immunodeficiency virus to transcribe viral RNA into DNA. Efavirenz is considered a non-nucleotide reverse transcriptase inhibitor because it does not have a structure based off of a nucleotide like
 Unlike most non-nucleotide reverse transcriptase inhibitors, efavirenz is also a 5-HT<sub>2A</sub> partial agonist, similar to [[LSD]]. Additionally, efavirenz is a [[serotonin]] and [[dopamine]] [[reuptake inhibitor]] and a vesicular monoamine transporter 2 inhibitor. Efavirenz also acts as a [[GABA]]<sub>A</sub> positive allosteric modulator, similar to [[benzodiazepines]] and [[barbiturates]].<ref> Neuropsychopharmacology | http://www.nature.com/npp/journal/v38/n12/full/npp2013135a.html</ref> Efavirenz has a bioavailability of about 40-45% when it is taken on an empty stomach.